The confirmed transmission of dengue fever virus (DENV) to three recipients by organs taken from a person who had spent time in the French West Indies, followed by the death of a kidney recipient one week after the transplant, was reported in November 2023, despite no circulating virus had been detected in the donor's blood at the time of harvesting. At the request of the General Directorate of Health (Direction générale de la santé), this event prompted the High Council of public health (Haut Conseil de la Santé Publique:HCSP) to consider whether more sensitive virological tests would improve the safety of donations of human body products from donors considered to be at risk. In addition to its opinion of November 28, 2020, the HCSP updated the literature and took the advice of the Centre national de référence des arbovirus. As a result, the HCSP now recommends, for organ donations, a search for DENV viral genome by RT-PCR test not only in blood but also in urine, as well as detection of IgM class anti-DENV antibodies in blood; decision algorithms for living or deceased donors considered at risk of dengue summarize the various proposals. For hematopoietic stem cell donors considered to be at risk of dengue fever, the decision to transplant is based exclusively on the detection of the viral genome in the donor's blood whenever possible. Recommendations for other products derived from the human body remain unchanged.